Trial Condition(s):

Carcinoma, Hepatocellular, Carcinoma, Renal Cell

Regulatory Post Marketing Surveillance Study on Nexavar®

Bayer Identifier:

14792

ClinicalTrials.gov Identifier:

NCT01012011

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

Inclusion Criteria
- Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.

Trial Summary

Enrollment Goal
2845
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 

Trial Design